CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that it will present detailed data from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumab at the 10th Clinical Trials on Alzheimer’s Disease Conference meeting in Boston. The webcasts will be live on Thursday, November 2, 2017 at approximately 3:30 p.m. ET (fixed-dose cohorts at up to 36 months) and Saturday, November 4, 2017 at approximately 11:15am ET (titration cohort at up to 24 months). To access the live webcasts, please visit the Investor’s section of Biogen’s website at www.biogen.com/investors. An archived version of the webcasts will be available following the presentation.
About Biogen
At Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. Founded in 1978 as one of
the world’s first global biotechnology companies by Charles Weissman and
Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has
the leading portfolio of medicines to treat multiple sclerosis; has
introduced the first and only approved treatment for spinal muscular
atrophy; and is focused on advancing neuroscience research programs in
Alzheimer’s disease and dementia, neuroimmunology, movement disorders,
neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute
neurology. Biogen also manufactures and commercializes biosimilars of
advanced biologics. We routinely post information that may be important
to investors on our website at www.biogen.com.
To learn more, please visit www.biogen.com
and follow us on social media – Twitter,
LinkedIn,
Facebook,
YouTube.